))
Lagevrio questions, mRNA jab misunderstandings and nasal vaccines coming
Manage episode 344368145 series 3382357
Content provided by healthedaustralia. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by healthedaustralia or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Episode 207
Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time
COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed
How the Pfizer vaccination’s lack of impact on transmission is not a cause for concern and was clearly communicated since its release. The main impact is the reduction of severity, hospitalisations and death, and the data for this hasn’t changed
How a nasal vaccination might be coming
Host: David Lim | Total Time: 21 mins
Guest: A/Prof Paul Griffin, Infectious Diseases Physician and Clinical Microbiologist
Register for our fortnightly FREE WEBCASTS
Every second Tuesday | 7:00pm-9:00pm AEDT
Click here to register for the next one
See omnystudio.com/listener for privacy information.
100 episodes
Share
